Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 최한곤 | - |
dc.date.accessioned | 2018-08-31T08:06:14Z | - |
dc.date.available | 2018-08-31T08:06:14Z | - |
dc.date.issued | 2009-03 | - |
dc.identifier.citation | VASCULAR PHARMACOLOGY, v. 50, No. 3-4, Page. 123-131 | en_US |
dc.identifier.issn | 1537-1891 | - |
dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S1537189108001432 | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/74703 | - |
dc.description.abstract | Angiogenesis plays a critical role in the pathogenesis of malignant tumor growth and metastases. Since cyclooxygenase (COX)-2 expression is positively correlated with vascular endothelial growth factor (VEGF) expression and enhanced angiogenesis, COX-2 inhibitors have been focused on as angiogenesis-inhibiting drugs that may offer a complementary modality to classical strategies for cancer therapy. In this study, we evaluated the potential antiangiogenic effects of 1-furan-2-yl-3-pyridin-2-yl-propenone (FPP-3), a dual COX/5-LOX inhibitor. In HT1080 cancer cells, FPP-3 significantly suppressed release of VEGF as well as activation of NF-kappa B. a transcriptional factor required for VEGF expression. In a chick chorioallantoic membrane (CAM) assay, FPP-3 dose-dependently suppressed VEGF- and MCF-7 human breast cancer cell-induced angiogenesis. In experiments with human umbilical vein endothelial cells (HUVECs), FPP-3 dose-dependently decreased not only the cell survival and proliferation but also the tube formation and invasion using Matrigel-coated plates. Such antiangiogenic activity correlated with suppression of VEGF-induced matrix metalloproteinase (MMP)-2 expression, reactive oxygen species (ROS) production, and extracellularly regulated kinase (ERK) phosphorylation. Furthermore, in contrast to the case of NS398, a selective COX-2 inhibitor, FPP-3 did not alter the ratio of tissue factor (TF)/tissue factor pathway inhibitor (TFPI) expression, a coagulation index. These results indicate that FPP-3 could be used as an effective antiangiogenic agent without the risk of developing thrombotic complications. (c) 2008 Elsevier Inc. All rights reserved. | en_US |
dc.description.sponsorship | This work was supported by grant no. RT104-01-04, from the Regional Technology Innovation Program of the Ministry of Commerce, Industry, and Energy (MOCIE). | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | ELSEVIER SCIENCE INC | en_US |
dc.subject | Propenone | en_US |
dc.subject | COX-2 | en_US |
dc.subject | Tumor angiogenesis | en_US |
dc.subject | ROS | en_US |
dc.subject | pERK | en_US |
dc.subject | Tissue factor | en_US |
dc.title | The anti-angiogenic effects of 1-furan-2-yl-3-pyridin-2-yl-propenone are mediated through the suppression of both VEGF production and VEGF-induced signaling | en_US |
dc.type | Article | en_US |
dc.relation.no | 3-4 | - |
dc.relation.volume | 50 | - |
dc.identifier.doi | 10.1016/j.vph.2008.11.006 | - |
dc.relation.page | 123-131 | - |
dc.relation.journal | VASCULAR PHARMACOLOGY | - |
dc.contributor.googleauthor | Park, Byung Chul | - |
dc.contributor.googleauthor | Park, Su-Young | - |
dc.contributor.googleauthor | Lee, Jong-Suk | - |
dc.contributor.googleauthor | Mousa, Shaker A | - |
dc.contributor.googleauthor | Kim, Jong Tae | - |
dc.contributor.googleauthor | Kwak, Mi-Kyoung | - |
dc.contributor.googleauthor | Kang, Keon Wook | - |
dc.contributor.googleauthor | Lee, Eung-Seok | - |
dc.contributor.googleauthor | Choi, Han Gon | - |
dc.contributor.googleauthor | Yong, Chul Soon | - |
dc.contributor.googleauthor | Kim, Jung-Ae | - |
dc.relation.code | 2009214177 | - |
dc.sector.campus | E | - |
dc.sector.daehak | COLLEGE OF PHARMACY[E] | - |
dc.sector.department | DEPARTMENT OF PHARMACY | - |
dc.identifier.pid | hangon | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.